CYP1A2 and breast cancer: For CYP1A2 rs11636419, under the dominant model breast cancer patients with the combined genotype (GG+AG) were more likely to have a younger age, a pre-menopause status and a P53 negative tumor relative to patients with the AA genotype (P = 0.025, 0.002 and 0.011, respectively, Table 1).